AU2001294647A1 - Method or treatment of tumors using transforming growth factor-alpha - Google Patents

Method or treatment of tumors using transforming growth factor-alpha

Info

Publication number
AU2001294647A1
AU2001294647A1 AU2001294647A AU9464701A AU2001294647A1 AU 2001294647 A1 AU2001294647 A1 AU 2001294647A1 AU 2001294647 A AU2001294647 A AU 2001294647A AU 9464701 A AU9464701 A AU 9464701A AU 2001294647 A1 AU2001294647 A1 AU 2001294647A1
Authority
AU
Australia
Prior art keywords
tumors
alpha
treatment
growth factor
transforming growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294647A
Inventor
Andrzej Sledziewski
Daniel R. Twardzik
Alan Upshall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stem Cell Pharmaceuticals Inc
Original Assignee
Stem Cell Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stem Cell Pharmaceuticals Inc filed Critical Stem Cell Pharmaceuticals Inc
Publication of AU2001294647A1 publication Critical patent/AU2001294647A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
AU2001294647A 2000-09-22 2001-09-20 Method or treatment of tumors using transforming growth factor-alpha Abandoned AU2001294647A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23515200P 2000-09-22 2000-09-22
US60235152 2000-09-22
PCT/US2001/029742 WO2002024148A2 (en) 2000-09-22 2001-09-20 Method or treatment of tumors using transforming growth factor-alpha

Publications (1)

Publication Number Publication Date
AU2001294647A1 true AU2001294647A1 (en) 2002-04-02

Family

ID=22884304

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294647A Abandoned AU2001294647A1 (en) 2000-09-22 2001-09-20 Method or treatment of tumors using transforming growth factor-alpha

Country Status (3)

Country Link
US (1) US20020077291A1 (en)
AU (1) AU2001294647A1 (en)
WO (1) WO2002024148A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60035192T2 (en) * 1999-04-26 2008-02-14 Applied Protein Sciences, LLC, Mountain View TGF-ALPHA POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHOD FOR THEIR USE
US20020193301A1 (en) * 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
JP2007509611A (en) * 2003-10-17 2007-04-19 アクティス バイオロジクス， インコーポレイテッド Lentiviral vector delivery of MSP36 to treat cancer
WO2005065309A2 (en) * 2003-12-31 2005-07-21 Actis Biologics, Inc. Lentiviral vector delivery of native and mutated igfbp-3 for treatment of cancer
EP1943173B1 (en) * 2005-11-01 2011-09-21 Ferag AG Method of, and apparatus for, transferring sheet-like products from a stack of products to a conveying belt
US8389501B2 (en) * 2011-07-17 2013-03-05 Saifullah Anticancer compound
AU2018222735B2 (en) * 2017-02-17 2023-04-27 George Todaro Use of TGF alpha for the treatment of diseases and disorders

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
EP0154434B1 (en) * 1984-02-17 1993-01-27 Genentech, Inc. Human transforming growth factor and precursor or fragment thereof, cells, dna, vectors and methods for their production, compositions and products containing them, and related antibodies and diagnostic methods
US4749683A (en) * 1985-01-25 1988-06-07 President And Fellows Of Harvard College Inhibition of gastric acid secretion with alpha-transforming growth factor
CA1275922C (en) * 1985-11-28 1990-11-06 Harunobu Amagase Treatment of cancer
US4874746A (en) * 1987-12-22 1989-10-17 Institute Of Molecular Biology, Inc. Wound headling composition of TGF-alpha and PDGF
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
US5102870A (en) * 1989-04-14 1992-04-07 Schering Ag Treatment and prevention of oral mucositis with growth factors
JPH04352800A (en) * 1990-10-26 1992-12-07 Childrens Medical Center Corp:The Smooth muscle mitogen
US5229493A (en) * 1990-10-26 1993-07-20 Children's Medical Center Corporation Smooth muscle mitogen
US5886141A (en) * 1990-10-26 1999-03-23 Takeda Chemical Industries, Ltd. Smooth muscle mitogen peptides and DNA coding therefor
US5604202A (en) * 1990-11-13 1997-02-18 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Use of NGF growth factors to treat drug-induced neuropathy
US5851832A (en) * 1991-07-08 1998-12-22 Neurospheres, Ltd. In vitro growth and proliferation of multipotent neural stem cells and their progeny
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5980885A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. Growth factor-induced proliferation of neural precursor cells in vivo
US6071889A (en) * 1991-07-08 2000-06-06 Neurospheres Holdings Ltd. In vivo genetic modification of growth factor-responsive neural precursor cells
US5981165A (en) * 1991-07-08 1999-11-09 Neurospheres Holdings Ltd. In vitro induction of dopaminergic cells
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US5656465A (en) * 1994-05-04 1997-08-12 Therion Biologics Corporation Methods of in vivo gene delivery
DE69626034T2 (en) * 1995-11-09 2003-08-14 Takeda Chemical Industries Ltd COMPOSITION FOR IMPROVING PANCREAS FUNCTION
US5814308A (en) * 1996-03-26 1998-09-29 Zhang; Ke Methods for the treatment of gastrointestinal tract disorders
AU5530198A (en) * 1996-12-16 1998-07-15 Zymogenetics Inc. Compositions and methods for stimulating pancreatic islet cell regeneration
EP1175487A2 (en) * 1999-02-10 2002-01-30 Curis, Inc. Pancreatic progenitor cells, methods and uses related thereto
US6037357A (en) * 1999-04-21 2000-03-14 Unitech Pharmaceuticals, Inc. N-benzoyl-α-alkylated azatyrosines as anticancer agents
US6852528B2 (en) * 2000-03-24 2005-02-08 Cell Genesys, Inc. Human and mouse uroplakin II gene transcriptional regulatory elements

Also Published As

Publication number Publication date
WO2002024148A2 (en) 2002-03-28
WO2002024148A3 (en) 2002-06-06
US20020077291A1 (en) 2002-06-20

Similar Documents

Publication Publication Date Title
AU2001249881A1 (en) Method of treating the heart
AU2001229712A1 (en) Reduction of hair growth
AU2002257936A1 (en) Methods of well treatment
AU2002215125A1 (en) Well treatment method
AU2001286983A1 (en) Method of treatment
AUPQ533700A0 (en) Soil treatment method
AU2001247600A1 (en) Methods of modulating hair growth
AU2001285747A1 (en) Method for the treatment of tobacco
AU2001240046A1 (en) Method of treating skin conditions
AU2001232263A1 (en) Method of treating seeds
AU2002320510A1 (en) Method of improving plant growth
AU2001294647A1 (en) Method or treatment of tumors using transforming growth factor-alpha
AU2001287668A1 (en) Method for the sterilisation of objects
AU2001253836A1 (en) Method of treating cancer
AU2002231683A1 (en) Method of producing alk-3-ene-1-ols
AU2001262177A1 (en) Method of treatment
AUPR731901A0 (en) Method of treatment
AU2002210584A1 (en) Method for treatment of dredging soil
AU4598400A (en) Method of treatment
AU2001253560A1 (en) Methods of treatment
AU2382601A (en) Novel method of treatment
AUPR213000A0 (en) Method of treatment
AUPQ949500A0 (en) Method of treatment
AUPQ662500A0 (en) Method of treatment
AUPQ790400A0 (en) Treated seed production system & method